Investigational New Drugs

, Volume 35, Issue 2, pp 127–133 | Cite as

Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies

  • Alexandra Tyulyandina
  • Daniel Harrison
  • Wei Yin
  • Evgenia Stepanova
  • Dmitry Kochenkov
  • Eliso Solomko
  • Nina Peretolchina
  • Frits Daeyaert
  • Jean-Baptiste Joos
  • Koen Van Aken
  • Mikhail Byakhov
  • Evgenia Gavrilova
  • Sergei Tjulandin
  • Ilya Tsimafeyeu
PRECLINICAL STUDIES
  • 372 Downloads

Summay

Purpose Early data suggest that combining FGFR2 inhibitors with platinum-containing cytotoxic agents for the treatment of epithelial ovarian cancer may yield increased antitumor activity. We investigated antitumor activity of alofanib (RPT835), a novel allosteric FGFR2 inhibitor, in ovarian cancer in vitro and in vivo. Methods Equal amounts of ovarian cancer cell (SKOV3) lysates were analyzed for FGFR1–3 protein expression using Wes. To assess the efficacy of alofanib on FGF-mediated cell proliferation, SKOV3 cells were incubated and were treated with serially diluted alofanib. Basic FGF was added at a concentration of 25 ng/ml. Control wells were left untreated. Cell growth inhibition was determined using Promega’s Cell Titer-Glo® assay. Immunocompromised mice were used for xenotransplantation of SKOV3 cancer cells. Seventy animals with measurable tumors were selected on day 10 and randomized into control groups (no treatment or chemotherapy alone (paclitaxel + carboplatin) and treatment groups (alofanib orally or intravenously (different dose levels) in combination with chemotherapy). Measurements of tumor volume (mm3) were performed by digital calipers every 3 days during 31 days after tumor inoculation. Number of tumor vessels and Ki-67 index were calculated. Results SKOV3 cells express FGFR1 and FGFR2 but not FGFR3. Basic FGF increased proliferation of the ovarian cancer cells in untreated control group (P = 0.001). Alofanib inhibited growth of FGFR2-expressing SKOV3 cells with GI50 value of 0.37 μmol/L. Treatment with alofanib in combination with paclitaxel/carboplatin resulted in tumor growth delay phenotype in all treatment groups compared to control non-treatment groups. Compound exhibited a dose-dependent effect on tumor growth. Daily intravenous regimen of alofanib (total maximum dose per week was 350 mg/kg) demonstrated significant effect (inhibiting growth by 80 % and by 53 % in comparison with vehicle and chemotherapy group alone, respectively (P < 0.001). Alofanib decreased number of vessels in tumor (−49 %; P < 0.0001) and number of Ki-67-positive SKOV3 cells (−42 %, P < 0.05). There were tumor necrosis and cell degeneration in alofanib group. Conclusions We suggest that FGFR2 inhibition has potent effects on ovarian cancer growth in preclinical studies.

Keywords

Alofanib RPT835 FGFR2 Allosteric inhibitor Ovarian cancer Preclinical studies 

References

  1. 1.
    Siegel R, Kimberly DM, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30CrossRefPubMedGoogle Scholar
  2. 2.
    Heintz AP, Odicino F, Maisonneuve P et al (2006) Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95(Supervision 1):S161–S192CrossRefPubMedGoogle Scholar
  3. 3.
    Scully R, Young RH, Clement PB (1998) Surface epithelial-stromal tumors and serous tumors. In: Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. District of Columbia: Armed Forces Institute of Pathology, Washington, p. 51Google Scholar
  4. 4.
    NCCN Clinical Practice Guidelines. Ovarian cancer ver.1 2016 https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf
  5. 5.
    Klar M, Hasenburg A, Hasanov M, Hilpert F, Meier W, Pfisterer J et al (2016) Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO study group. GINECO and NSGO Eur J Cancer 66:114–124CrossRefPubMedGoogle Scholar
  6. 6.
    Tsimafeyeu I, Khasanova A, Stepanova E, Gordiev M, Khochenkov D, Naumova A et al (2016) FGFR2 overexpression predicts survival outcome in patients with metastatic papillary renal cell carcinoma. Clin Transl Oncol 5 [Epub ahead of print]. doi:10.1007/s12094-016-1524-y
  7. 7.
    Luo Y, Yang C, Jin C, Xie R, Wang F, McKeehan WL (2009 Sep) Novel phosphotyrosine targets of FGFR2IIIb signaling. Cell Signal 21(9):1370–1378CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Tyulyandina A, Tsimafeyeu I, Demidova I, Gikalo M, Tjulandin S FGFR2 amplification in serous ovarian cancer. Cancer Res 76(14 Supplement):4586–4586Google Scholar
  9. 9.
    Cole C, Lau S, Backen A, Clamp A, Rushton G, Dive C et al (2010 Sep 1) Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer. Cancer Biol Ther 10(5):495–504CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Tsimafeyeu I, Ludes-Meyers J, Stepanova E, Daeyaert F, Kochenkov D, Joose JB et al (2016) Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models. Eur J Cancer 61:20–28CrossRefPubMedGoogle Scholar
  11. 11.
    Tsimafeyeu I, Daeyaert F, Joos JB, Aken KV, Ludes-Meyers J, Byakhov M et al (2016) Molecular modeling, de novo design and synthesis of a novel, extracellular binding fibroblast growth factor receptor 2 inhibitor alofanib (RPT835). Med Chem 12(4):303–317CrossRefPubMedGoogle Scholar
  12. 12.
    Chen L, Wu X, Ruan J, Liang Y, Ding Y, Shi Z et al (2004) Screening novel, potent multidrug-resistant modulators from imidazole derivatives. Oncol Res 14:355–362PubMedGoogle Scholar
  13. 13.
    Tsimafeyeu I, Zaveleva E, Stepanova E, Low W (2013) OM-RCA-01, a novel humanized monoclonal antibody targeting fibroblast growth factor receptor 1, in renal cell carcinoma model. Investig New Drugs 31(6):1436–1443CrossRefGoogle Scholar
  14. 14.
    Eichbaum M, Mayer C, Eickhoff R, Bischofs E, Gebauer G, Fehm T et al (2011) The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer. BMC Cancer 11:453CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L et al (2008) Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret hospital phase II consortia. J Clin Oncol 26:76–82CrossRefPubMedGoogle Scholar
  16. 16.
    Previs RA, Armaiz-Pena GN, Lin YG, Davis AN, Pradeep S, Dalton HJ et al (2015) Dual metronomic chemotherapy with Nab-paclitaxel and Topotecan has potent antiangiogenic activity in ovarian cancer. Mol Cancer Ther 14(12):2677–2686CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Alexandra Tyulyandina
    • 1
  • Daniel Harrison
    • 2
  • Wei Yin
    • 2
  • Evgenia Stepanova
    • 3
  • Dmitry Kochenkov
    • 3
  • Eliso Solomko
    • 3
  • Nina Peretolchina
    • 3
  • Frits Daeyaert
    • 4
  • Jean-Baptiste Joos
    • 5
  • Koen Van Aken
    • 5
  • Mikhail Byakhov
    • 6
  • Evgenia Gavrilova
    • 7
  • Sergei Tjulandin
    • 1
  • Ilya Tsimafeyeu
    • 7
  1. 1.Department of Clinical Pharmacology and Chemotherapy, N.N. Blokhin Russian Cancer Research CenterMoscowRussia
  2. 2.Altogen LabsAustinUSA
  3. 3.Laboratory of biomarkers and mechanisms of tumor angiogenesis, N.N. Blokhin Russian Cancer Research CenterMoscowRussia
  4. 4.FD ComputingBeerseBelgium
  5. 5.EcoSynthOostendeBelgium
  6. 6.Moscow Clinical and Research CenterMoscowRussia
  7. 7.Ruspharmtech LLCSaint PetersburgRussia

Personalised recommendations